Does Ozempic or Wegovy Work Better for Weight Loss?

Last reviewed: June 6, 2026

Last updated: June 6, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Ozempic and Wegovy represent the same medication—semaglutide—but serve different markets and carry vastly different price tags. Clinical trials show semaglutide produces average weight loss of 15% body weight over 68 weeks when combined with lifestyle changes. Understanding how these products compare can help you make an informed decision about which option fits your health goals and budget.

The Core Similarity: Both Contain Semaglutide

Ozempic and Wegovy are identical in their active pharmaceutical ingredient—semaglutide—a glucagon-like peptide-1 (GLP-1) receptor agonist. The difference lies in FDA approval pathway and marketing strategy. Ozempic received approval for type 2 diabetes management, while Wegovy earned separate FDA clearance specifically for chronic weight management in adults with obesity or overweight with weight-related conditions. Both medications work by mimicking the GLP-1 hormone, which signals fullness to your brain and slows stomach emptying.

The PlexusDx Precision Peptide Genetic Test analyzes GIPR, FTO, and MC4R — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to semaglutide or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

Clinical Evidence: Weight Loss Results Across Studies

The STEP trials, which evaluated semaglutide for weight loss, showed participants lost an average of 10.2 kg (22.5 lbs) with the 1 mg dose and 15.3 kg (33.7 lbs) with the 2.4 mg dose over 68 weeks. These results represent approximately 10-15% of baseline body weight reduction—a clinically significant outcome. Participants who combined semaglutide with structured diet and exercise achieved the highest results. The medication worked for approximately 70-80% of study participants, though individual response rates varied based on genetic predisposition and adherence.

Head-to-head comparisons between Ozempic-labeled semaglutide and Wegovy-labeled semaglutide show no meaningful difference in weight loss efficacy when administered at equivalent doses. The distinction is purely regulatory and commercial. Your genetic profile—including variants in GIPR gene (rs1800437)—influences how effectively your body responds to semaglutide, regardless of which brand you use.

Price Comparison: Why Wegovy Costs More Than Ozempic

Ozempic carries an average retail price of $800-$1,000 monthly, while Wegovy costs $1,300-$1,500 monthly for the same medication at equivalent doses. Insurance sometimes covers Ozempic for diabetes but rarely covers Wegovy for weight loss, creating a significant out-of-pocket burden for many patients. These price differences persist despite identical active ingredients and manufacturing standards. The markup reflects different marketing channels, FDA indication exclusivity, and pharmaceutical company pricing strategies rather than any clinical superiority.

PlexusDx compounded semaglutide injection is $189/mo month-to-month (or $149/mo on the 6-month plan) across all doses, with no insurance requirement and no membership fees. Because PlexusDx sources from licensed 503A compounding pharmacies, pricing remains flat regardless of your dose level—your dose may need to go up, but your price won't. This model removes the financial barrier that prevents many patients from accessing evidence-based GLP-1 therapy. HSA and FSA accounts cover PlexusDx medications, providing additional savings pathways.

Compounded Semaglutide vs. Brand-Name Alternatives

Compounded medications prepared by licensed 503A pharmacies contain the same semaglutide molecule as Ozempic and Wegovy. The FDA distinguishes between 503A compounders (traditional pharmacies) and 503B manufacturers (sterile compounding facilities), and PlexusDx exclusively partners with 503A licensed compounding pharmacies to ensure quality and safety standards. Compounded semaglutide undergoes the same pharmaceutical testing for purity, potency, and sterility as branded versions. The primary difference is the distribution channel and pricing model, not the medication's chemical composition or effectiveness.

The PlexusDx Precision Peptide Genetic Test ($298) analyzes GIPR, FTO, and MC4R — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to semaglutide or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

Which Option Should You Choose?

Your choice between Ozempic, Wegovy, and compounded semaglutide should center on three factors: cost accessibility, insurance coverage likelihood, and whether genetic-guided treatment appeals to you. If your insurance covers Ozempic for diabetes-related weight loss, that may be your lowest-cost option with full coverage. If you pay out-of-pocket, Wegovy's brand premium makes it the most expensive choice. PlexusDx compounded semaglutide offers the broadest accessibility for uninsured and underinsured patients without sacrificing clinical quality.

The PlexusDx Precision Peptide Genetic Test analyzes GIPR, FTO, and MC4R — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to semaglutide or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

Is compounded semaglutide as safe as Ozempic or Wegovy?

Yes. Compounded semaglutide from licensed 503A pharmacies contains identical active ingredients and meets the same pharmaceutical standards for purity and potency as brand-name versions. The clinical safety and efficacy data apply equally across all semaglutide sources when prescribed at appropriate doses. PlexusDx medications come from accredited compounding pharmacies and are reviewed by board-certified clinicians.

Can insurance cover PlexusDx semaglutide instead of Ozempic?

Insurance coverage policies vary by plan, but many plans cover compounded medications when prescribed for FDA-approved indications. PlexusDx operates without requiring insurance, making it accessible for uninsured patients. HSA and FSA accounts cover PlexusDx semaglutide, and you can explore insurance reimbursement with your provider for compounded prescriptions.

How does the Precision Peptide Genetic Test help with semaglutide?

No — the Precision Peptide Genetic Test does not predict your response to semaglutide or any specific medication. It analyzes pathway-level variants (GIPR, FTO, and MC4R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

Why does Wegovy cost more than Ozempic if they're the same medication?

Wegovy carries a price premium because it's marketed exclusively for weight loss under a separate FDA indication and brand identity, while Ozempic is primarily marketed for diabetes. Insurance coverage differs between them—Ozempic may be covered for diabetes-related conditions, while Wegovy is rarely covered for weight management. These marketing and coverage differences drive the $400-$500 monthly price gap despite identical active ingredients.

What dose of semaglutide will I need, and will my price increase?

Semaglutide dosing typically starts at 0.25 mg weekly and escalates every four weeks, with most patients reaching a therapeutic dose of 1.0-2.4 mg weekly. PlexusDx pricing remains flat at $189/mo month-to-month, or from $149/mo on the 6-month plan regardless of your final maintenance dose level. This pricing structure removes the financial barrier that discourages patients from reaching their optimal therapeutic dose.

Related Reading

• Wegovy For Weight Loss 2
• Ozempic For Weight Loss 2
• Average Weight Loss On Ozempic
• Wegovy Weight Loss Pills

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.